Research programme: fixed combinations for cardiovascular indications - HanAll Biopharma

Drug Profile

Research programme: fixed combinations for cardiovascular indications - HanAll Biopharma

Alternative Names: HL013 (hypertension/hyperlipidemia functional combination) - HanAll Biopharma; HL037; HL053; HL162

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HanAll Biopharma
  • Class
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hyperlipidaemia; Hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperlipidaemia in South Korea (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hypertension in South Korea (PO)
  • 08 Feb 2011 This programme is ongoing in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top